Merck's (NYSE:MRK) experimental antibody drug conjugate zilovertamab vedotin, in combination with standard of care, ...

Figure 1: Antibodies from AChR-Ab–seronegative MG patients bind to MuSK. Figure 3: MuSK IgG antibodies induce AChR clusters but inhibit agrin-induced clustering. COS7 cells were plated onto ...

Protein tyrosine ... kinase by interfering with the binding of ATP or substrates. Other anti-TK drugs may inhibit activation of fusion TKs by blocking their dimerization. Antibodies against ...

Antibody drug conjugates have a novel mechanism of action ... HER3, human epidermal growth factor receptor 3; PD, progressive disease. Fig 2. Kaplan-Meier plots of (A) PFS and (B) DOR, both by BICR ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Mesenchymal epithelial transition (MET) proto-oncogene receptor tyrosine kinase (RTK) is a cell surface receptor selective for hepatocyte growth factor (HGF), and is involved in embryogenesis ...

One of the novel pathways under investigation is the inhibition of Bruton tyrosine kinase ... Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of ...

The IMPROVE study investigated whether a three-week pause in BTKi therapy around the time of COVID-19 vaccination would improve the antibody ... continued Bruton tyrosine kinase inhibitor use ...